TST002 Intervenous Injection in Postmenopausal Women and Men With Reduced Bone Mineral Density

Phase 1

• Conditions: Osteoporosis
• Interventions: Drug: placebo; Drug: TST002 Injection

• Registration Number: NCT05391776
• Lead Sponsor: HJB (Hangzhou) Co., Ltd.

Brief Summary

This is a placebo-controlled, single-ascending dose, multicenter Phase I clinical study to evaluate the safety, tolerability, PK and PD characteristics of a single intravenous infusion of TST002 in subjects with reduced bone mineral density.

Detailed Description

Four single dose cohorts are designed in this study, ascending with phase I dose-escalation principles as following: 200mg, 400mg (100%), 800mg (100%), and 1200mg (50%). 8 subjects will be enrolled in each cohort, 6 for TST002 injection and 2 for placebo. Only ≤3 male subjects could be enrolled in each cohort. Subjects in each dose group were randomized to receive TST002 or placebo in a ratio of 3:1.

Study Timeline

• Study Start: 2022-04-28
• Status Verified: 2022-05
• Study First Submitted: 2022-05-16
• Study First Submitted QC: 2022-05-20
• Last Update Submitted: 2022-05-20
• Study First Posted: 2022-05-26
• Last Update Posted: 2022-05-26
• Primary Completion: 2023-04-28
• Study Completion: 2023-06-28

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 32

Inclusion Criteria

Subjects must meet all of the following inclusion and exclusion criteria to be enrolled in this study:

1. Voluntarily signe the informed consent, could walk freely, understood the study and is willing to follow it, and could complete all test procedures as planned;
2. Body mass index (BMI) : 18.0-30.0 kg/m2 (inclusive), weight ≥45 kg, BMI= weight (kg)/height 2 (m2);
3. 45-70 years old (inclusive) postmenopausal women who have been in post-menopause for 2 years or more. Menopause is defined as: 1) no spontaneous vaginal bleeding or bleeding for more than 12 months; 2) More than 1 year after bilateral oophorectomy (time for unilateral oophorectomy is calculated according to natural menopause); 3) Hysterectomy: more than 50 years old, serum FSH level & GT; 40 iu/L. 50-75 years old (inclusive) men. Male subjects should agree to use effective, investigator-approved contraceptive methods from the time they sign the informed consent until 3 months after administration.
4. BMD T score at lumbar vertebra L1-L4, total hip or femoral neck < -1.0;
5. Subjects had at least two consecutive vertebrae in L1-L4 and at least one hip bone available for dual-energy DXA bone mineral density assessment;
6. Prior to enrollment, the investigator assessed the subjects to have no medical conditions that would significantly affect the study or may increase additional health risks by asking for medical history, physical examination, and supplementary examination. If the subjects have abnormal examination reports, they can only be enrolled if the investigator evaluates that they do not pose a safety risk to the subjects or do not interfere with the safety evaluation of the clinical study, and explains the reasons.

Exclusion Criteria

1. Blood donation or bleeding of 400mL or more within 3 months before screening; History of blood transfusion within 3 months prior to screening;

2. People who have a history of drug allergy or allergic constitution;

3. Received systemic glucocorticoid treatment 3 months before screening, and took prednisone equivalent of more than 5mg per day for a total of more than 10 days; Inhalation or topical administration within 2 weeks prior to screening is not included;

4. Have a history of alcohol or drug abuse or tobacco abuse in the past year (smoking more than 5 cigarettes per day).

   Note: Criteria for alcohol intake: weekly alcohol intake &lt; 14 units/week, 1 unit =360 mL beer; Or 150 mL wine; Or 45 mL white wine;

5. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) is greater than 1.25 times the upper limit of normal value or total bilirubin is greater than 1.1 times the upper limit of normal value; Renal function laboratory examination is judged to be clinically significant by researchers.

6. History of breast cancer (female subjects only); Hereditary family history of breast cancer or known BRCA1/2 gene mutation; Mammography within 6 months prior to screening does not exclude breast cancer.

7. Have a history of thrombocytopenia, or have a platelet count below the lower limit of the normal range during screening;

8. It is clinically significant to have previous diseases or hemorrhagic diseases leading to coagulation abnormalities or coagulation abnormalities during screening period;

9. Those who had a serious injury or major surgical operation within 1 month prior to the screening period, or who planned to have surgery during the study period;

10. History of solid organ and bone marrow transplants;

11. Participated in any clinical trials within 3 months prior to screening.

12. Other conditions that, in the investigator's judgment, are unsuitable for study participation, such as factors that, in the investigator's judgment, pose a risk to the safety of the subject or interfere with the study evaluation, procedure, or completion.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
A single ascending dose of placebo Intervenous Injection	placebo	Four single dose cohorts are designed in this study, 8 subjects will be enrolled in each cohort, Subjects in each dose group were randomized to receive TST002 or placebo in a ratio of 3:1.
A single ascending dose of TST002 Intervenous Injection	TST002 Injection	Four single dose cohorts are designed in this study, 8 subjects will be enrolled in each cohort, Subjects in each dose group were randomized to receive TST002 or placebo in a ratio of 3:1.

Primary Outcome Measures

Name	Time	Method
Adverse Event	Adverse events were collected from the time informed consent was signed until 12 weeks after the end of treatment	An AE is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Secondary Outcome Measures

Name	Time	Method
Tmax	2 hours before treatment and 12 weeks after treatment	Time to Maximum Observed Concentration of TST002.
Cmax	2 hours before treatment and 12 weeks after treatment.	Maximum Observed Concentration of TST002
T1/2	2 hours before treatment and 12 weeks after treatment.	Half-life Associated With the Terminal Phase of Elimination for TST002
P1NP	2 hours before treatment and days 8,29,43,57 and 85	Percent Change From Baseline in Procollagen TYpe 1 N-terminal Propeptide
BDM	baseline and day 85	Percent change from baseline in Bone Mineral Density at L1-L4,total hip and femoral neck
Immunogenicity	2 hours before treatment and days 15,29 and 85	Positive rate and timing of anti-TST002 antibody and neutralizing antibody
Serum total osteostatin	2 hours before treatment and 12 weeks after treatment	Percent change from baseline in serum total sclerostin
CL	2 hours before treatment and 12 weeks after treatment	System clearance rate of TST002

Trial Locations

Locations (3)

The First Affiliated Hospital of Henan University of Science and Technology; 🇨🇳 Luoyang, Henan, China

West China Hospital，Sichuan University; 🇨🇳 Chengdu, Sichuan, China

Nanjing Drum Tower Hospital; 🇨🇳 Nanjing, Jiangsu, China